Precision Biosciences - DTIL STOCK NEWS

Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, has announced its participation in two upcoming investor conferences. The company will be part of a panel discussion titled 'Expanding Platform Potential' at the Longwood Boston CEO Conference on October 28, 2024, at 11:10 AM ET.

Additionally, Precision BioSciences will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 11, 2024, at 3:00 PM ET at the InterContinental Boston. A live webcast of this event will be available on the company's website, with an archived replay accessible for approximately 30 days after the event.

Precision BioSciences utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits.

Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, announced a poster presentation at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress in Rome, Italy, from October 22-25, 2024. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion.

The presentation, titled 'High-efficiency homology-directed insertion into the genome using engineered homing endonucleases', will be delivered by Dr. Adam Mischler, Senior Scientist at Precision BioSciences Gene Discovery. The poster (Number #PO678) will be presented on Thursday, October 24, 2024, from 6:00-7:30pm CEST. This presentation highlights Precision BioSciences' advancements in gene editing technology, particularly in addressing diseases where a defective gene requires the expression of a new DNA sequence.

Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on October 8, 2024. The company, which utilizes its proprietary ARCUS® platform for developing in vivo gene editing therapies, will present during a fireside chat at 11:00 AM ET.

The presentation will be accessible via webcast, with registration available through a provided link. Investors can also view the presentation on Precision's website under the Investors section, Events & Presentations. An archived replay will be available for approximately 30 days after the event.

Precision BioSciences (Nasdaq: DTIL) has submitted Clinical Trial Applications (CTA) to initiate a Phase 1 study for PBGENE-HBV, its in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV). The therapy aims to eliminate cccDNA, the key source of replicating HBV, while also inactivating integrated HBV DNA in hepatocytes.

This marks the first gene editing approach for chronic hepatitis B, targeting an estimated 300 million people globally affected by the disease. The company's regulatory package is supported by robust non-human primate safety studies and efficacy in numerous preclinical models. Precision BioSciences plans to initiate the global Phase 1 trial soon and expects to report data in 2025.

Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, has announced the grant of inducement awards to two new employees under its 2021 Employment Inducement Incentive Award Plan. The awards, approved by the Compensation Committee on September 18, 2024, include:

1. Stock options to purchase 66,523 shares of common stock with a per-share exercise price of $9.60, vesting 25% after one year and the remaining 75% in quarterly installments over three years.

2. 1,841 restricted stock units (RSUs) vesting in equal annual installments over three years.

These awards were granted under Nasdaq Listing Rule 5635(c)(4) as inducements for the employees to join Precision BioSciences. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision.

Precision BioSciences (Nasdaq: DTIL) has announced key changes to its clinical leadership team, strengthening its capabilities in infectious diseases and hepatitis. Murray Abramson, MD, MPH has been appointed as Senior Vice President, Head of Clinical Development, overseeing all clinical activities including the lead PBGENE-HBV program. John Fry joins as Strategic Clinical Advisor, specializing in hepatitis and supporting the PBGENE-HBV clinical development strategy. These appointments come as Precision prepares to initiate development of its first in vivo gene editing candidate for hepatitis.

Additionally, Alan List, MD, Chief Medical Officer, will retire effective September 13, 2024, transitioning to a role as clinical consultant and member of Precision's Scientific Advisory Board. These changes aim to bolster the company's expertise as it advances its gene editing therapies, with anticipated Phase 1 data milestones for PBGENE-HBV in 2025.

Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, announced its participation in the H.C. Wainwright 26th Annual Global Healthcare Conference from September 9-11, 2024 in New York. The company will be involved in two key events:

1. A panel discussion on 'Cutting-Edge Approaches to Viral Hepatitis: Is a Cure on the Horizon?' on September 9, 2024, from 11:00-12:00PM ET, featuring Dr. Cassie Gorsuch, VP of Gene Therapy Discovery.

2. A fireside chat on September 10, 2024, from 5:00-5:30PM ET, which will be available via webcast on Precision's website for approximately 30 days after the event.

Precision BioSciences utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision.

Precision BioSciences (Nasdaq: DTIL) has received $13 million from Imugene as part of their August 2023 azer-cel deal. The payment includes $9.75 million in cash and $3.25 million in Imugene shares. This reinforces Precision's expected cash runway into the second half of 2026. The company is focusing on in vivo gene editing and plans to generate Phase 1 clinical data across multiple programs starting in the first half of 2025. Precision is also preparing to file applications for PBGENE-HBV for chronic hepatitis B later this year. The company had approximately $123.6 million in cash and cash equivalents as of June 30, 2024, before receiving the Imugene payment.

Precision BioSciences (Nasdaq: DTIL) announced that its partner TG Therapeutics has received FDA clearance for its Investigational New Drug (IND) Application to investigate Azercabtagene Zapreleucel (azer-cel) in human clinical trials for progressive forms of multiple sclerosis. Azer-cel is an experimental allogeneic CAR T therapy developed by Precision BioSciences and licensed to TG Therapeutics for autoimmune diseases. TG Therapeutics plans to start a phase 1 clinical trial in 2024.

In January 2024, Precision BioSciences licensed azer-cel to TG Therapeutics for autoimmune diseases, receiving $17.5 million in upfront and near-term economics, with potential for up to $288 million in milestone payments and high-single-digit to low-double-digit royalties on net sales.